$1.02 Million in Sales Expected for Dextera Surgical Inc. (DXTR) This Quarter
Analysts forecast that Dextera Surgical Inc. (NASDAQ:DXTR) will report sales of $1.02 million for the current quarter, according to Zacks. Two analysts have provided estimates for Dextera Surgical’s earnings, with estimates ranging from $830,000.00 to $1.20 million. Dextera Surgical posted sales of $470,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 117%. The business is scheduled to issue its next earnings results on Monday, November 6th.
According to Zacks, analysts expect that Dextera Surgical will report full-year sales of $1.02 million for the current fiscal year, with estimates ranging from $5.10 million to $5.19 million. For the next financial year, analysts expect that the business will report sales of $12.84 million per share. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Dextera Surgical.
Dextera Surgical (NASDAQ:DXTR) last issued its quarterly earnings results on Tuesday, August 8th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.29. The company had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $1.03 million.
Several equities research analysts have issued reports on DXTR shares. Wedbush cut their price objective on shares of Dextera Surgical from $3.50 to $0.70 and set an “outperform” rating for the company in a research report on Wednesday, July 12th. Zacks Investment Research upgraded shares of Dextera Surgical from a “sell” rating to a “hold” rating in a research report on Friday, June 30th. Finally, Ladenburg Thalmann Financial Services started coverage on shares of Dextera Surgical in a research report on Wednesday, August 16th. They set a “buy” rating and a $0.80 price objective for the company.
A number of hedge funds have recently modified their holdings of the business. Broadfin Capital LLC lifted its position in Dextera Surgical by 64.7% during the second quarter. Broadfin Capital LLC now owns 987,520 shares of the medical instruments supplier’s stock worth $296,000 after acquiring an additional 388,080 shares during the last quarter. Virtu KCG Holdings LLC raised its position in shares of Dextera Surgical by 1,380.6% in the second quarter. Virtu KCG Holdings LLC now owns 369,918 shares of the medical instruments supplier’s stock valued at $111,000 after buying an additional 344,933 shares in the last quarter. Finally, Perkins Capital Management Inc. acquired a new stake in shares of Dextera Surgical in the second quarter valued at approximately $100,000. Hedge funds and other institutional investors own 7.78% of the company’s stock.
Shares of Dextera Surgical (NASDAQ DXTR) traded down 1.55% during trading on Tuesday, reaching $0.33. The company had a trading volume of 2,408,231 shares. The firm has a 50 day moving average price of $0.29 and a 200 day moving average price of $0.56. Dextera Surgical has a 12 month low of $0.17 and a 12 month high of $2.33. The company’s market cap is $5.87 million.
Dextera Surgical Company Profile
Dextera Surgical Inc, formerly Cardica, Inc, designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Dextera Surgical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dextera Surgical Inc. and related stocks with our FREE daily email newsletter.